TSThais Prado de Souza

Thais Prado de Souza

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Thais Prado de Souza has a total of 25 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Antiproliferative activities in vitro of novel palladium(II) indole thiosemicarbazones complexes and Molecular Docking Studies with DNA

    by Thais Prado de Souza, Rafael Souza, Luana da Silva Dorneles, Claudio T. Carvalho, Gabriele de Menezes Pereira, Pedro P. Corbi, Isabella Cristina Prescilio, Fillipe Vieira Rocha, Javier Ellena, Carolina Oliveira

    Two new indole-based thiosemicarbazone ligands, HT1 and HT2, were synthesized by condensation of 3-methyl-1H-indol-2-carboxaldehyde with 4-methyl and 4-phenyl-3-thiosemicarbazide, respectively. These ligands were used to prepare four palladium(II) complexes containing triphenylphosphine (PPh3) or 1,3,5-triaza-7-phosphaadamantane (PTA), namely PdT1PPh3 (1), PdT1PTA (2), PdT2PPh3 (3) and PdT2PTA (4). The compounds were characterized by spectroscopic methods, HRMS, and single-crystal X-ray diffraction for HT1. Spectroscopic techniques (FTIR and NMR) indicated coordination of the ligands to palladium ion via nitrogen and sulfur atoms. HRMS analyses provided further confirmation of the proposed molecular formulations and the structural integrity of the ligands and complexes. Single-crystal X–ray diffraction confirmed the molecular structure of HT1 and revealed its solid-state organization driven by hydrogen-bonding interactions. The synthesized complexes containing PTA exhibited significantly greater cytotoxicity than their analogs containing PPh3. PdT1PTA and PdT2PTA complexes showed IC50 values in the submicromolar range for both A2780 cells (IC50 = 0.108 ± 0.023 µM and 0.146 ± 0.008 µM) and the cisplatin-resistant A2780cis cell line (IC50 = 0.427 ± 0.044 µM and 0.122 ± 0.033 µM), while maintaining lower toxicity to non-tumor MRC-5 fibroblasts (IC50 = 1.8 ± 0.4 µM and 2.87 ± 0.48 µM). PdT2PTA was the most active and selective derivative, while PdT2PPh3 showed no antiproliferative effects. LIVE/DEAD fluorescence imaging assays performed with PdT2PTA in A2780cis cells revealed a dose-dependent reduction in viable cell count. Exploratory molecular docking studies suggested favorable DNA-binding interactions for PdT2PTA, followed by PdT1PTA, in agreement with the antiproliferative results.

  • Open Access

    Dinuclear palladium(II) and platinum(II) complexes with thiosemicarbazide ligands: Structural characterization, antiproliferative activity and topoisomerase I docking studies

    by Thais Prado de Souza, Lucas Bonelli, Rafael Souza, Adelino V. G. Netto, Fillipe Vieira Rocha, Pamela Candido, Ronaldo Junio de Oliveira, Pedro Ivo da da Silva Maia, Victor Deflon, Carolina Oliveira

    The present work reports the synthesis, characterization and biological application as antiproliferative agents of two new thiosemicarbazides and four binuclear platinum(II) and palladium(II) complexes. The ligands H2LCh and H2LPh were used for the synthesis of four novel complexes [{Pd(LCh)Cl(PPh3)}2] (1), [{Pd(LPh)Cl(PPh3)}2] (2), [{Pt(LCh)Cl(PPh3)}2] (3), and [{Pt(LPh)Cl(PPh3)}2] (4). The compounds were characterized by spectroscopic methods such as FTIR, 1H and 31P NMR. Single–crystal X–ray diffraction confirmed the proposed structure for complexes 1, 2 and 3. In all cases, the Schiff base ligands coordinate in a bidentate mode via imine nitrogen and sulfur atoms, with two metal centers, forming dinuclear complexes. Additional donor atoms as a phosphorus from PPh3 ligand and a chlorine ion complete the coordination sphere with a square-planar geometry. The theoretical prediction of the interaction of the human topoisomerase enzyme with the dinuclear complexes of Pd(II) and Pt(II) shows that the complexes with the phenyl groups couple better and more favorably mainly through bond interactions and hydrophobic interactions. The antiproliferative properties in vitro of the free ligands and metal complexes have been investigated against A2780 (ovarian tumor), A2780cis (cisplatin–resistant ovarian tumor), A549 (lung tumor), SK–BR-3 (breast tumor) and MRC–5 (non–lung tumor of fetal origin). The results show an increase in activity after the complexation of the thiosemicarbazide to metal centre of palladium(II) against ovarian cancer cells.

  • Open Access

    A New Heteroleptic Zn(II) Complex with Schiff Bases Sensitizes Triple-Negative Breast Cancer Cells to Doxorubicin and Paclitaxel

    by Raiane Aparecida dos Santos Machado, Raoni Pais Siqueira, Fernanda Cardoso da Silva, André Carlos Pereira de Matos, Dayanne Silva Borges, Gislaine Gonçalves Rocha, Thais Cristina Prado de Souza, Rafael Aparecido Carvalho Souza, Clayton Rodrigues de Oliveira, Antônio G. Ferreira, et al.

    Background/Objectives: Triple-negative breast cancer (TNBC) is the most challenging molecular subtype of breast cancer (BC) in clinical practice, associated with a worse prognosis due to limited treatment strategies and its insensitivity to conventional drugs. Zinc is an important trace element for homeostasis, and its Schiff base metal complexes have shown promise in treating advanced tumors. In this study, four new heteroleptic Zn(II) complexes (1–4) with Schiff bases were synthesized, characterized, and evaluated for their activity in BC cells. Methods: Compounds were synthesized, characterized, and their crystal structures were determined. Biological activity was assessed using MTT, clonogenic, scratch wound healing, caspase 3 and 8 activity, qPCR, and chemosensitization assays. Results: The complexes exhibited cytotoxicity against MCF-7 (luminal BC), MDA-MB-453 (HER2-positive BC), and MDA-MB-231 (TNBC) cell lines, with IC50 values ranging from 0.01 to 20 µM. Complex 4 showed reduced cytotoxicity toward non-tumor cell lines. This, complexation with Zn(II) increased the cytotoxicity of the ligands, a trend not observed for complexes 1–3. Due to its favorable profile, complex 4 was selected for further assays, in which it inhibited colony formation and the cell migration of TNBC cells in a dose-dependent manner. Furthermore, this compound induced cell death independently of caspases, decreasing the activity of caspase 8. Interestingly, complex 4 sensitized TBNC cells to doxorubicin and paclitaxel, possibly modulating the epithelial–mesenchymal transition mechanism, as evidenced by increased CDH1 expression. Conclusions: Results suggest the potential of complex 4 in sensitizing aggressive BC cells to chemotherapy, proving to be a promising alternative in cases of therapeutic failure.